Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects

References

• Garcia-Navarro X, Puig L, Fernández-Figueras MT, et al. Bortezomib-associated cutaneous vasculitis. Br J Dermatol 2007;157:799–801
   PubMed Web of Science ®Google Scholar
• Mariz JM, Esteves GV. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Curr Opin Oncol 2012;24:S3–S11
   PubMed Web of Science ®Google Scholar
• CTCAE_4.03_2010-06-14.xls s.d. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html [last accessed 23 Apr 2013]
   Google Scholar
• Van de Donk NW, Görgün G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012;4:253–268
   PubMedGoogle Scholar
• Borovicka JH, Calahan C, Gandhi M, et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011;147:1403–1409
   PubMed Web of Science ®Google Scholar
• Bonny M, Buyse V, Brochez L. Dermatological side effects of current and upcoming targeted therapies in oncology. Acta Clin Belg 2011;66:97–103
   PubMed Web of Science ®Google Scholar
• Myskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 2009;3:294–299
   PubMedGoogle Scholar
• Sviggum HP, Davis MDP, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006;142:1298–1302
   PubMed Web of Science ®Google Scholar
• Min C-K, Lee S, Kim Y-J, et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 2006;76:265–268
   PubMed Web of Science ®Google Scholar
• Van Regenmortel N, Van de Voorde K, De Raeve H, et al. Bortezomib-induced Sweet’s syndrome. Haematologica 2005;90:ECR43
   PubMedGoogle Scholar
• Sanchez-Politta S, Favet L, Kerl K, et al. Bortezomib-induced skin eruption. Dermatology (Basel) 2008;216:156–158
   PubMed Web of Science ®Google Scholar
• Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J. Am Acad Dermatol 2006;55:897–900
   PubMed Web of Science ®Google Scholar
• Ozkurt ZN, Sucak GT, Aki SZ, et al. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma. Cutan Ocul Toxicol 2009;28:141–143
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006;134:391–398.
   PubMed Web of Science ®Google Scholar
• Agterof MJ, Biesma DH. Images in clinical medicine. Bortezomib-induced skin lesions. N Engl J Med 2005;352:2534
   PubMedGoogle Scholar
• Pour L, Hajek R, Zdenek A, et al. Skin lesions induced by bortezomib. Haematologica 2005;90:ECR44
   PubMedGoogle Scholar
• Tanguy-Schmidt A, Avenel-Audran M, Croué A, et al. Bortezomib-induced acute neutrophilic dermatosis. Ann Dermatol Venereol 2009;136:443–446
   PubMed Web of Science ®Google Scholar
• Thomas M, Cavelier Balloy B, et al. Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration. Ann Dermatol Venereol 2009;136:438–442
   PubMed Web of Science ®Google Scholar
• Thuillier D, Lenglet A, Chaby G, et al. Bortezomib-induced eruption: sweet syndrome? Two case reports. Ann Dermatol Venereol 2009;136:427–430
   PubMed Web of Science ®Google Scholar
• Knoops L, Jacquemain A, Tennstedt D, et al. Bortezomib-induced Sweet syndrome. Br J Haematol 2005;131:142
   PubMedGoogle Scholar
• Varettoni M, Vassallo C, Borroni G, et al. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol 2007;86:301–302
   PubMed Web of Science ®Google Scholar
• Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003;48:548–552
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9–19
   PubMed Web of Science ®Google Scholar
• Kuohung V, Goldberg LJ, Demierre M-F. Lenalidomide-induced purpuric eruption: a new adverse cutaneous reaction. J Am Acad Dermatol 2011;65:654–656
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37
   PubMed Web of Science ®Google Scholar
• Berg SL, Cairo MS, Russell H, et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children’s Oncology Group Phase I Consortium report. J Clin Oncol 2011;29:316–323
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–4053
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006;107:2609–2616
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459–4465
   PubMed Web of Science ®Google Scholar
• Castelli R, Cannavò A, Conforti F, et al. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol Immunotoxicol 2012;34:740–753
   PubMed Web of Science ®Google Scholar
• Siniscalchi A, Tendas A, Morino L, et al. Lenalidomide cutaneous adverse event: a case of Stevens--Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Support Care Cancer 2012;20:1585–1587
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Reece DE, Trudel S, et al. Lenalidomide (revlimid), bortezomib (velcade) and dexamethasone (rvd) for heavily-pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma 2013;54:555--560
   Google Scholar
• Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749–760
   PubMed Web of Science ®Google Scholar
• Castaneda CP, Brandenburg NA, Bwire R, et al. Erythema multiforme/Stevens--Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol 2009;27:156–157
   PubMed Web of Science ®Google Scholar
• Wäsch R, Jakob T, Technau K, et al. Stevens--Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol 2012;91:287–289
   PubMed Web of Science ®Google Scholar
• Grape J, Frosch P. Papular drug eruption along the lines of Blaschko caused by lenalidomide. Hautarzt 2011;62:618–620
   PubMed Web of Science ®Google Scholar
• Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology (Basel) 2010;220:49–50
   PubMed Web of Science ®Google Scholar
• Tageja N, Giorgadze T, Zonder J. Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J 2011;41:286–288
   PubMed Web of Science ®Google Scholar
• Hoverson AR, Davis MDP, Weenig RH, Wolanskyj AP. Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide. Arch Dermatol 2006;142:1070–1071
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764–2767
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119–5125
   PubMed Web of Science ®Google Scholar